Information message

In order to see all the search results and access content, you must log in. Please use the Log-in button at the top of the page.

Displaying 1 - 12 of 431

EASL Policy Dialogues S3 E2: World Liver Day – Join us in celebrating liver health on a global scale

Description

World Liver Day (19 April) is a global event designed to celebrate liver health and empower the voices of the liver community in advocating for better prevention, detection, and care. Societies from around the world engaged in liver care come together each year to collectively raise the profile of liver health at the community, national, and international level. This year, EASL paves the way forward in Europe on World Liver Day with new educational resources, patient testimonials, and a user-friendly website, making it easier than ever to learn about and take care of the liver.

The EASL Policy Dialogues Season 3 is supported by Novo Nordisk. EASL has received no input from Novo Nordisk with regards to the content of the EASL Policy Dialogues Season 3.

The World Liver Day activities carried out under the umbrella of Healthy Livers, Healthy Lives, are supported by Boehringer Ingelheim, Echosens, MSD, and Novo Nordisk. Our industry partners have had no input into the content of the World Liver Day activities.

 

Speakers

 
Eduardo Lopez

Eduardo Lopez has been working as an Imaging Director at Fujifilm since 1994. After the diagnosis of his daughter, Mr. Lopez joined and became President of the Spanish Lysosomal Acid Lipase Deficiency Patient Organisation (AELALD). This is the only patient organization in Europe devoted to this rare disease which mainly affects the liver. Eduardo is also a board member of the Catalan Federation of Rare Diseases (FECAMM) and a member of the New Born Screening group at the European Organisation for Rare Disease (EURORDIS).

Shira Zelber-Sagi

Prof. Zelber-Sagi has graduated BSc in nutrition sciences from the Hebrew University and has 23 years of experience as a clinical dietitian with expertise in liver diseases, within the liver unit, at the Department of Gastroenterology Tel-Aviv Medical Center. She graduated with a Ph.D. in epidemiology and preventive medicine at the Sackler School of Medicine at Tel Aviv University. Since 2009, she has been a faculty at the University of Haifa, Faculty of Social Welfare and Health Sciences at the School of Public Health. Currently (in the past four years), she is the Head of the School of Public Health. Her research focuses on NAFLD epidemiology, prevention, and treatment combining nutrition, physical activity, weight reduction, and behavioral aspects. She was a member of the EASL Policy and Public Health Committee and the UEG Policy and Public Health Committee. She has published about 150 scientific papers and book chapters.

 

Log in to post comments
EASL Membership
Off

EASL Policy Dialogues S2 E9: Preventing liver disease with policy measures: The Hepahealth II study

Description

Chronic liver disease (CLD) causes 1.8% of all deaths in Europe. Without policies to mitigate harmful alcohol consumption and obesity, that proportion will continue to increase. In order to address this, EASL commissioned the Hepahealth II study, a validated and peer-reviewed miscrosimulation model, to project the impact of various policy scenarios designed to improve liver health in Europe. In this episode, Professors Maria Buti, Shira Zelber-Sagi, and Peter Jepsen introduce the study, its aims, and results. Finally, Alice Chapman-Hatchett discusses more broadly the policy situation in Europe and the challenges to implementing more health focused policies.

The Hepahealth II study has been supported by an unrestricted education grant from Bristol-Myers Squibb and Gilead. Bristol-Myers Squibb and Gilead have had no input into EASL content.

 

Speakers

 
maria buti

Maria Buti is currently Professor of Medicine and consultant of Hepatology at the Hospital General Universitari Valle Hebron, Barcelona and the EASL Public Health Councillor. Dr Buti has worked in viral hepatitis for the last 35 years, particularly in diagnosis and therapy of hepatitis B , C and D. She has published more than 500 papers the field of liver disease, with numerous papers and contributions to books.

Shira Zelber-Sagi

Prof. Zelber-Sagi is a clinical dietitian, Epidemiologist, and researcher in nutritional and lifestyle epidemiology, chronic diseases related to lifestyle, and public health aspects. Graduated BSc in nutrition sciences at the Hebrew University. Graduated with a Ph.D. in Epidemiology and Preventive Medicine at the Sackler School of Medicine at Tel Aviv University. Currently, she is a full Professor and Head of the School of Public Health, Faculty of Social Welfare and Health Sciences, University of Haifa. She is a member of the “National Committee for Nutrition, Gastroenterology, and Liver Disease”. Since June 2023, she has been an EASL Governing Board member and Public Health Councillor-elect. She is a United European Gastroenterology (UEG) Policy and Public Health Committee member, and the founder of the Gastroenterology and Hepatology Dietitians’ forum within the Israeli Dietitians Association. She has published over 150 scientific publications, mostly dealing with lifestyle and liver disease and other chronic diseases, including nutrition, physical activity, smoking, alcohol, and policy recommendations. Email: [email protected]

Peter Jepsen

Prof. Peter Jepsen is an EASL Policy and Public Health Committee Member. Born in 1975, graduated from the medical school in Aarhus, Denmark in 2003. Since then clinical training and specialisation in hepatology, alongside training in clinical epidemiology. Prof. Jepsen has published more than 100 papers, most of them in the field of hepato-epidemiology. He currently does half-time clinical work, half-time research. Prof. Jepsen's primary interests are alcoholic liver disease and hepatocellular carcinoma, most notably the value of surveillance for hepatocellular carcinoma among patients with alcoholic cirrhosis.

Alice Chapman-Hatchett

Alice Chapman-Hatchett is the Director of the Health and Europe Centre, a social enterprise in the National Health Service in the UK. The Centre works to bring European learning, practice, and policy to the local health community, improving patient outcomes and focusing on health inequalities and social determinants of health. Chapman is President of EPHA (European Public Health Alliance) and has over 13 years of experience working in public health in areas ranging from sexual health, NCDs, ageing, mental health, and health systems.

Log in to post comments

EASL Studio S6 E6: Alpha-1-antitrypsin deficiency (AATD): A poster child for genetic therapy

Description

On the eve of the rare disease day, our guests discuss the compelling reasons why AATD stands out as the prime candidate for gene therapy. This talk addresses the pertinence of the subject in the current research landscape and highlight ongoing global trials opening the door for new opportunities in this field.

Faculty

  • Aleksander Krag (Moderator)
  • Aftab Ala (Faculty)
  • Pavel Strnad (Faculty)
  • Alice Turner (Faculty)

Related episodes

This episode is scheduled in honour of the Rare Disease Day (29 February).

ℹ️ Please click here to access the podcast version of this EASL Studio episode.

Log in to post comments
EASL Membership
Off
Liver Tumours
EASL Journal Club: Inflamed and non-inflamed class of HCC: A revised immunogenomic classification

EASL Journal Club: Inflamed and non-inflamed class of HCC: A revised immunogenomic classification

EASL Journal Club
View
Liver Tumours
EASL Journal Club: Molecular characterisation of hepatocellular carcinoma in patients with non-alcoholic steatohepatitis

EASL Journal Club: Molecular characterisation of hepatocellular carcinoma in patients with non-alcoholic steatohepatitis

EASL Journal Club
View
Immune-Mediated and Cholestatic Diseases
EASL Journal Club: FXR inhibition may protect from SARS-CoV-2 infection by reducing ACE2

EASL Journal Club: FXR inhibition may protect from SARS-CoV-2 infection by reducing ACE2

EASL Journal Club
View
Immune-Mediated and Cholestatic Diseases
EASL Journal Club: Role of the IgG4-related cholangitis autoantigen annexin A11 in cholangiocyte protection

EASL Journal Club: Role of the IgG4-related cholangitis autoantigen annexin A11 in cholangiocyte protection

EASL Journal Club
View
Basic Science
EASL Journal Club: Single-cell atlas of human liver development reveals pathways directing hepatic cell fates

EASL Journal Club: Single-cell atlas of human liver development reveals pathways directing hepatic cell fates

EASL Journal Club
View
Viral Hepatitis
EASL Journal Club: Liver cancer risk after HCV cure in patients with advanced liver disease without non-characterized nodules

EASL Journal Club: Liver cancer risk after HCV cure in patients with advanced liver disease without non-characterized nodules

EASL Journal Club
View
Cirrhosis & Complications
EASL Journal Club: Performance of routine risk scores for predicting cirrhosis-related morbidity in the community

EASL Journal Club: Performance of routine risk scores for predicting cirrhosis-related morbidity in the community

EASL Journal Club
View
General Hepatology
EASL Journal Club: Risk factors and outcomes associated with recurrent autoimmune hepatitis following liver transplantation

EASL Journal Club: Risk factors and outcomes associated with recurrent autoimmune hepatitis following liver transplantation

EASL Journal Club
View
Metabolism, Alcohol & Toxicity
EASL Journal Club: Prognostic performance of 7 biomarkers compared to liver biopsy in early alcohol-related liver disease

EASL Journal Club: Prognostic performance of 7 biomarkers compared to liver biopsy in early alcohol-related liver disease

EASL Journal Club
View